IIM

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, MPV, IIM, MuSK protein, Toxicity, Conference, Disease, Dermatomyositis, Juvenile dermatomyositis, Federation, Patient, NOL, Observation, CRS, SLE, Health Canada, IND, Immunoglobulin therapy, Pemphigus, Investment, Investigational New Drug, Myopathy, Systemic scleroderma, Marketing, FDA, Clinical trial, Cytokine release syndrome, Cyclophosphamide, CD19, Food, Autoimmune disease, Pharmaceutical industry

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.

Key Points: 
  • In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.
  • In November 2023, Cabaletta announced that its IND application for CABA-201 was allowed to proceed by the FDA for the Phase 1/2 RESET-MG trial.
  • Cabaletta anticipates reporting initial clinical data from the Phase 1/2 RESET-MG trial in the second half of 2024.
  • As of December 31, 2023, Cabaletta had cash, cash equivalents and short-term investments of $241.2 million, compared to $106.5 million as of December 31, 2022.

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Retrieved on: 
Thursday, February 1, 2024
Clinical trial, Patient, Food, Myositis, ODD, Myopathy, IIM, Immune system, FDA, Marketing, Pharmaceutical industry

CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells.

Key Points: 
  • CABA-201 is in development as a potential treatment for autoimmune diseases driven by B cells.
  • Four RESET™ (REstoring SElf-Tolerance) Phase 1/2 trials are advancing for the evaluation of CABA-201 across multiple autoimmune conditions, including the Phase 1/2 RESET-Myositis™ trial.
  • “Myositis, believed to be driven by B cells, is a severe and potentially fatal autoimmune disease for which no curative therapy exists.
  • This designation qualifies Cabaletta for certain incentives, which may include partial tax credit for clinical trial expenditures, waived user fees and potential eligibility for seven years of marketing exclusivity.

Invesco Advisers, Inc. Announces Appointment of New Trustees for Closed-End Funds

Retrieved on: 
Thursday, January 18, 2024
Woman, VCV, General counsel, VBF, Principal, University, Economics, VVR, VTN, Insurance, JD, Communication, TIAA, VLT, OIA, Zions Bancorporation, Senior, Financial services, Head, IIM, McKinsey & Company, VKI, VGM, VMO, KPMG LLP, KPMG, Bank, Investment Company Institute, Fulbright Program, Management

ATLANTA, Jan. 18, 2024 /PRNewswire/ -- Invesco Advisers, Inc., a subsidiary of Invesco Ltd. (NYSE: IVZ), announced today that the Boards of Trustees (the "Boards") of Invesco Advantage Municipal Income Trust II (VKI), Invesco Bond Fund (VBF), Invesco California Value Municipal Income Trust (VCV), Invesco High Income 2024 Target Term Fund (IHTA), Invesco High Income Trust II (VLT), Invesco Municipal Income Opportunities Trust (OIA), Invesco Municipal Opportunity Trust (VMO), Invesco Municipal Trust (VKQ), Invesco Pennsylvania Value Municipal Income Trust (VPV), Invesco Quality Municipal Income Trust (IQI), Invesco Senior Income Trust (VVR), Invesco Trust for Investment Grade Municipals (VGM), Invesco Trust for Investment Grade New York Municipals (VTN) and Invesco Value Municipal Income Trust (IIM) (collectively, the "Funds") appointed Carol Deckbar, Jeffrey H. Kupor, James "Jim" Liddy and Douglas Sharp as trustees of the Funds, effective January 18, 2024.

Key Points: 
  • ATLANTA, Jan. 18, 2024 /PRNewswire/ -- Invesco Advisers, Inc., a subsidiary of Invesco Ltd. (NYSE: IVZ), announced today that the Boards of Trustees (the "Boards") of Invesco Advantage Municipal Income Trust II (VKI), Invesco Bond Fund (VBF), Invesco California Value Municipal Income Trust (VCV), Invesco High Income 2024 Target Term Fund (IHTA), Invesco High Income Trust II (VLT), Invesco Municipal Income Opportunities Trust (OIA), Invesco Municipal Opportunity Trust (VMO), Invesco Municipal Trust (VKQ), Invesco Pennsylvania Value Municipal Income Trust (VPV), Invesco Quality Municipal Income Trust (IQI), Invesco Senior Income Trust (VVR), Invesco Trust for Investment Grade Municipals (VGM), Invesco Trust for Investment Grade New York Municipals (VTN) and Invesco Value Municipal Income Trust (IIM) (collectively, the "Funds") appointed Carol Deckbar, Jeffrey H. Kupor, James "Jim" Liddy and Douglas Sharp as trustees of the Funds, effective January 18, 2024.
  • Martin Flanagan, who had served as an interested trustee of the Funds, has retired from that role effective January 18, 2024.
  • Each trustee currently serves on the boards of trustees of the open-end and interval fund investment companies in the Invesco funds complex.
  • This communication is not intended to, and shall not, constitute an offer to purchase or sell shares of any of the Invesco funds, including the Funds.

Konica Minolta Expands Relationship with OMNIA Partners

Retrieved on: 
Tuesday, January 9, 2024
Minolta, Konica Minolta, Scientific Research Publishing, IIM, IT service management, GPO, System, Safety, Group purchasing organization, Organization, BPO, Intelligence

Ramsey, NJ, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) is pleased to announce a new, ten-year agreement with Group Purchasing Organization (GPO) OMNIA Partners.

Key Points: 
  • Ramsey, NJ, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) is pleased to announce a new, ten-year agreement with Group Purchasing Organization (GPO) OMNIA Partners.
  • Building on the 25-year history of partnering with OMNIA Partners, Konica Minolta will offer an innovative suite of technology and services to members of OMNIA Partners Private Sector.
  • The significant success of our relationship with OMNIA Partners is attributable to the combined efforts of the sales and executive teams of both organizations,” said Sam Errigo, President and CEO, Konica Minolta.
  • We take pride in offering our members access to a broad array of industry leading suppliers and are excited to have Konica Minolta continue as part of our comprehensive portfolio,” said Todd Abner, President and CEO, OMNIA Partners.

MIRAI JMAC & Royal Family Office of UAE Announce Formation of MIRAI Capital Global With Its First Tranche of USD 1.5 Billion Investment Fund for ASIA-USA-UAE Corridor

Retrieved on: 
Wednesday, November 29, 2023
Finance, Start-Up, Consulting, Professional Services, Other Professional Services, BoA, Investment, Risky Business (House), Strategic partnership, Marketing, IIT Madras, LFO scandal, Family, MBA, Development, Business, Partner (business rank), B2B, Organization, Amazon, Vinoth, Real estate, Multimedia, CXO, USD, BNP Paribas, AI, Real estate investing, Silicon, Morgan Stanley, Business transformation, Royal, Region, Partner, EMBA, University, Partnership, Management, Discover Financial, Lead, Private officer of arms, Venture capital, Highness, IIM, Fintech, RFO, City, Private equity, Emirates NBD, Private, Environment, Financial services, Drug, Health care, Manufacturing, Dhilip Varman, Far East

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    “I intend to build the biggest global partnership & investment vehicle for the world and enhance the visibility of my diversified portfolio via MIRAI Capital Global,” said H.H.
  • “Our goal at MIRAI JMAC to connect large family offices with strategic investment opportunities and MIRAI Capital Global is a culmination of that mission,” said Pranav Jyoti, Co-founder and Managing Director of MIRAI Capital Global.
  • At MIRAI Capital, we aim to harness this smart capital, becoming the top choice for entrepreneurs and fund managers seeking global expansion.
  • MIRAI Capital Global, via RFO, has built a strong pipeline of strategic opportunities that will ultimately build a bridge for the India–UAE–US corridor in 2024-25.

Rapidus and Tenstorrent Partner to Accelerate Development of AI Edge Device Domain Based on 2nm Logic

Retrieved on: 
Friday, November 17, 2023
Research, Engineering, IP, LSI, IBM, IIM, Innovation, Intellectual property, CPU, Partnership, Rapidus, AI, EUV, Integration

In addition to its AI processors and servers, Tenstorrent built and owns the world's most performant RISC-V CPU IP and licenses that technology to its customers around the world.

Key Points: 
  • In addition to its AI processors and servers, Tenstorrent built and owns the world's most performant RISC-V CPU IP and licenses that technology to its customers around the world.
  • Through this technological partnership with Rapidus, Tenstorrent will accelerate the development of cutting-edge devices to meet the needs of the ever-evolving digital society.
  • "Japan is very important both to Tenstorrent and to me personally," said David Bennett, Chief Customer Officer of Tenstorrent.
  • This will be Japan's first facility for the production of state-of-the-art logic semiconductors at 2-nanometers (nm) and beyond.

DigiDrub Welcomes Paresh Vankar as New Partner

Retrieved on: 
Wednesday, November 8, 2023
Knowledge, LTIMindtree, Organization, Creativity, Engineering, Growth, Indian Institutes of Management, Culture, HCLTech, IIM, Princeton University, Paresh, Marketing

Global Digital Experience Agency Enriches Leadership Team with Tech Marketing Leader

Key Points: 
  • Princeton, New Jersey--(Newsfile Corp. - November 8, 2023) - DigiDrub, a leading global digital experience agency that works on cutting-edge digital strategies and transformative customer experiences, is excited to announce that Paresh Vankar is joining the firm as a partner.
  • Paresh brings with him a wealth of knowledge and over two decades of high-level experience spearheading marketing initiatives within the technology sector.
  • "We're confident that with Paresh, DigiDrub will continue to set new benchmarks in the digital experience landscape and deliver even greater value to our clients."
  • "I am thrilled to join DigiDrub and work with a team that is as passionate about innovation in the digital space as I am," said Paresh Vankar.

Serenity shield champions blockchain's Role in Telecom at G20 Pre-Event

Retrieved on: 
Saturday, September 16, 2023
Gaia, Serenity, Blockchain, Web3, TEC, Constitution Club of India, IIM, Telecommunications, Speech, American Federation of Government Employees, Privacy, Indian Institute of Management Lucknow, Winston Hall, Organization, Ministry, IEEE, Student, Ministry of Defence, Panel discussion, CDAC, NIXI, G20, STPI, Conference, TRAI, Cryptocurrency, Indian Navy

The event, which precedes the G20 summit in India, was a significant platform for exploring blockchain's transformative potential across various industries.

Key Points: 
  • The event, which precedes the G20 summit in India, was a significant platform for exploring blockchain's transformative potential across various industries.
  • Venket Naga, CEO of Serenity Shield, was a keynote speaker, emphasizing the potential role of Web 3 and blockchain in enhancing data security in telecommunications.
  • His speech underscored Serenity Shield's dedication to blockchain technology and data security solutions, empowering organizations to harness blockchain's potential while ensuring data integrity and privacy.
  • Serenity Shield's presence at the conference alongside India's infrastructure giants underscores blockchain's legitimacy for integration within India's IT and Telecoms infrastructure.

2023 Dermatomyositis Pipeline Landscape Report Unveils Promising Growth Potential with 10+ Companies and Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023
Health, Pharmaceutical, Muscle weakness, Therapy, Rash, Myopathy, IIM, Pharmaceutical industry, Dermatomyositis

The "Dermatomyositis - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dermatomyositis - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights into the Dermatomyositis pipeline landscape, covering 10+ companies and 10+ pipeline drugs.
  • Dermatomyositis is a rare acquired immune-mediated muscle disease characterized by muscle weakness and skin rash.
  • The report includes detailed descriptions of pipeline drugs, such as Lenabasum by Corbus Pharmaceuticals and KZR-616 by Kezar Life Sciences, offering novel approaches to treat and improve Dermatomyositis.

New GrammarlyGO Features Empower Students to Use Generative AI Responsibly

Retrieved on: 
Tuesday, July 25, 2023
Education, Data Management, Technology, Software, Other Education, Artificial Intelligence, Workforce, Learning, Communication, IIM, Howard University, Feedback, Synthetic media, ChatGPT, Research, Privacy, Thought, Harvard Medical School, Literacy, Student, Indian Institute of Management Ahmedabad, Johns Hopkins University, Guideline, AI, Cornell University, Nursing, Book

Grammarly , the company delivering AI communication assistance to over 30 million people, 50,000 professional teams, and 3,000 educational institutions daily, today announced new features that guide students in leveraging generative AI to augment—not replace—their critical thinking and communication skills.

Key Points: 
  • Grammarly , the company delivering AI communication assistance to over 30 million people, 50,000 professional teams, and 3,000 educational institutions daily, today announced new features that guide students in leveraging generative AI to augment—not replace—their critical thinking and communication skills.
  • These features will start rolling out in late August in GrammarlyGO , the on-demand, generative AI-powered tool that works everywhere students do, in time for the 2023/24 school year.
  • Auto-citations simplify citing generative AI, enabling ethical use and transparency for educators: Grammarly will now offer customers the ability to generate a citation for text generated by tools such as GrammarlyGO and ChatGPT.
  • AI guideline reminders assist students in responsibly using generative AI: GrammarlyGO will discourage students from generating long-form text if they attempt to do so, with messaging within the product that redirects them to ideate with GrammarlyGO instead while reminding them to adhere to their institution’s or instructor’s policies.